⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934228 | 0.94 | — | — | |
| SCHEMBL23344 | 0.94 | — | — | |
| Trimethylammonium SCHEMBL2150496 | 0.80 | — | — | |
| Isopropyl Alcohol SCHEMBL29164092 | 0.76 | ALDH1A1 (0.86) | — | |
| Isopropyl Alcohol SCHEMBL9066428 | 0.76 | — | — | |
| Ammonia Solution, Strong SCHEMBL6442671 | 0.76 | — | — | |
| Isopropyl Alcohol SCHEMBL3680075 | 0.76 | ALDH1A1 (0.86) | — | |
| Isopropyl Alcohol SCHEMBL28380595 | 0.76 | ALDH1A1 (0.86) | — | |
| Ammonia Solution, Strong SCHEMBL1863656 | 0.76 | — | — | |
| Isopropyl Alcohol SCHEMBL42097 | 0.76 | ALDH1A1 (0.86) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410988-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A DRUG AND SIRNA | Novartis AG (CH) | 2012-02-01 | — | — | EP | claimed |
| JP-4838514-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| WO-2010108934-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A DRUG AND SIRNA | NOVARTIS AG (CH) | 2010-09-30 | — | — | WO | claimed |
| EP-2152274-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINES | Questor Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008137960-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINES | QUESTOR PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1658053-A2 | NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE | Elan Pharma International Limited (IE) | 2006-05-24 | — | — | EP | claimed |
| EP-1613276-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | Elan Pharma International Limited (IE) | 2006-01-11 | — | — | EP | claimed |
| EP-1596830-A1 | NOVEL FLUTICASONE FORMULATIONS | Elan Pharma International Limited (IE) | 2005-11-23 | — | — | EP | claimed |
| WO-2005013937-A2 | NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-02-17 | — | — | WO | claimed |
| WO-2004069225-A1 | NOVEL FLUTICASONE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004050059-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-06-17 | — | — | WO | claimed |
| US-20250297287-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING THE NEONATAL FC RECEPTOR | APELLIS PHARMACEUTICALS, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12264331-B2 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025050114-A1 | COMPOSITIONS AND METHODS FOR TARGETED UBIQUITINATION OF THE VOLTAGE-GATED SODIUM CHANNEL NAV1.8 | YALE UNIVERSITY (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12214055-B2 | Systems and methods for treating hyper-igm syndrome | EDITAS MEDICINE INC. | 2025-02-04 | — | — | US | disclosed |
| EP-1196145-A1 | METHODS AND APPARATUS FOR PREPARATION OF LIPID VESICLES | Inex Pharmaceuticals Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001097829-A2 | COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1109539-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001005373-A1 | METHODS AND APPARATUS FOR PREPARATION OF LIPID VESICLES | INEX PHARMACEUTICALS CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000013677-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2000-03-16 | — | — | WO | disclosed |